Denali Therapeutics (DNLI) Non-Current Assets (2017 - 2026)

Denali Therapeutics (DNLI) has 10 years of Non-Current Assets data on file, last reported at $243.3 million in Q1 2026.

• Quarterly Non-Current Assets fell 38.05% year-over-year to $243.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $892.0 million (down 56.74% YoY) and the FY2025 annual result came in at $244.2 million, down 52.09% from the prior year.
• Non-Current Assets was little changed at $243.3 million in Q1 2026 per DNLI's latest filing, from $244.2 million in the prior quarter.
• Across five years, Non-Current Assets topped out at $607.5 million in Q1 2024 and bottomed at $81.7 million in Q2 2023.
• The 5-year median for Non-Current Assets is $231.5 million (2025), against an average of $270.5 million.
• The widest annual swing landed in 2022, when Non-Current Assets plunged 82.66%; it then surged 621.67% in 2024.
• Tracing DNLI's Non-Current Assets over 5 years: stood at $87.9 million in 2022, then increased by 2.11% to $89.8 million in 2023, then surged by 467.77% to $509.7 million in 2024, then slumped by 52.09% to $244.2 million in 2025, then dropped by 0.38% to $243.3 million in 2026.
• Per Business Quant, the three latest DNLI Non-Current Assets figures stand at $243.3 million (Q1 2026), $244.2 million (Q4 2025), and $173.0 million (Q3 2025).

Peer Comparison